Clinical Trials Logo

Filter by:
NCT ID: NCT01827592 Terminated - Clinical trials for Chronic Idiopathic Constipation

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Start date: April 2013
Phase: Phase 3
Study type: Interventional

Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.

NCT ID: NCT01826448 Terminated - Clinical trials for V600-mutated BRAF Metastatic Melanoma

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Start date: November 5, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to test the safety of an investigational new drug called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose levels. Vemurafenib has been approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of unresectable or metastatic melanoma.

NCT ID: NCT01826344 Terminated - Clinical trials for Abdominal Aortic Aneurysms (AAA)

The Vascutek Custom Fenestrated Anaconda Post-Market Surveillance Study

Start date: June 2010
Phase: N/A
Study type: Observational [Patient Registry]

This is a multicentre, prospective, observational post-market registry (follow-up 1 month, 1 year, 2 years, 3 years, 4 years and 5 years) to monitor the post-market clinical safety and effectiveness of the Vascutek AnacondaTM Custom Fenestrated Stent Graft in patients with a short infrarenal neck of <15mm or juxta-renal abdominal aortic aneurysms who, in the opinion of the treating physician, are anatomically suitable for the AnacondaTM Custom Fenestrated Stent Graft and for whom a customised medical device is required.

NCT ID: NCT01820325 Terminated - Clinical trials for Non-Small Cell Lunch Cancer

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

BASALT-2
Start date: September 9, 2013
Phase: Phase 1
Study type: Interventional

The Phase Ib part of the study aimed to determine the maximum tolerated dose/recommended Phase II dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin and paclitaxel in patients with previously untreated metastatic squamous NSCLC. The purpose of the Phase II portion of the study was to assess the treatment effect of adding buparlisib versus buparlisib-matching placebo to every-three-week carboplatin and paclitaxel on progression free survival (PFS) in patients with previously untreated metastatic squamous NSCLC.

NCT ID: NCT01817738 Terminated - Prostate Cancer Clinical Trials

Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the new RNActive®-derived prostate cancer vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic metastatic prostate cancer that is castrate resistant.

NCT ID: NCT01814956 Terminated - Clinical trials for Parenteral Nutrition

Different Lipid Emulsions in Acute Lung Injury Patients

Start date: March 2013
Phase: Phase 4
Study type: Interventional

Aim is to investigate the influence of an early supply of parenteral nutrition including a fish oil containing lipid emulsion on the course of acute lung injury in the intensive care unit. In comparison, a standard parenteral nutrition with a soybean oil based emulsion will be used. Data obtained in this trial may provide evidence for a beneficial effect of fish oil derived omega-3 fatty acids in parenteral nutrition regarding their influence on acute lung injury.

NCT ID: NCT01811875 Terminated - Haemophilia A Clinical Trials

Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A

Start date: November 21, 2014
Phase: Phase 4
Study type: Interventional

Primary objective: To assess post-marketing immunogenicity of Optivate® by monitoring plasma inhibitor levels for at least 100 Exposure Days (EDs) for each subject. Secondary objectives: To assess efficacy and tolerability by monitoring FVIII recovery and adverse events

NCT ID: NCT01809782 Terminated - Clinical trials for Delirium and Post-operative Cognitive Dysfunction (POCD)

Cognitive Outcome After Two-stage Liver-Operation

2-StaLi
Start date: March 11, 2013
Phase: N/A
Study type: Observational

Cognitive outcome (delirium and post-operative cognitive deficiency) in patients undergoing two-time liver resection.

NCT ID: NCT01808950 Terminated - Clinical trials for Nodular Basal Cell Carcinoma

Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.

NCT ID: NCT01808261 Terminated - Clinical trials for Cerebrovascular Accident

Proof of Concept (POC) in Patients With Ischaemic Stroke

Start date: May 18, 2013
Phase: Phase 2
Study type: Interventional

Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.